BGI Genomics (华大基因)

BGI Genomics Launches PCOS Mass Spectrometry Diagnostic Solution

BGI Genomics unveiled a comprehensive mass spectrometry diagnostic solution for Polycystic Ovary Syndrome (PCOS) at the ICG21·RH conference. This innovative solution aims to provide accurate and efficient diagnosis for women of reproductive age, utilizing advanced mass spectrometry technology to improve early detection and management of PCOS, thereby supporting reproductive health.

BGI Genomics Launches ALS Research Center and AI Agent 'ZhiJian'

BGI Genomics has established an Amyotrophic Lateral Sclerosis (ALS) Multi-Omics Joint Research Center and launched the ALS knowledge intelligent agent named 'ZhiJian'. This initiative aims to advance research into ALS by integrating multi-omics data and leveraging artificial intelligence for knowledge discovery and application. The center and AI agent are expected to accelerate understanding of ALS pathogenesis and facilitate the development of new diagnostic and therapeutic strategies.

BGI Genomics Launches Huayi Smart Terminals with Huawei

BGI Genomics, in collaboration with Huawei and Runda Medical, has officially launched the Huayi™ series of smart terminals. This partnership aims to integrate advanced technology into healthcare solutions, enhancing diagnostic and monitoring capabilities. The launch signifies a step towards more connected and intelligent healthcare ecosystems, leveraging the strengths of each participating company to deliver innovative medical devices.

BGI Genomics Home Test Detects Precancerous Polyp

A news report highlights how a home stool test, facilitated by BGI Genomics' technology, helped detect a 2cm polyp that posed a significant risk of developing into colon cancer. The individual, Mr. Liu from Harbin, was able to identify this precancerous lesion early, averting a potential cancer diagnosis and emphasizing the importance of accessible screening methods.

BGI Group Leads National Nanopore Sequencing Project for Pathogen Detection

On March 15, 2026, BGI Group initiated a national key R&D program focused on developing convenient, long-read sequencing systems for pathogen detection. This project, part of a national science and technology initiative, involves nine leading domestic institutions. The goal is to accelerate the application of nanopore sequencing technology in diagnosing infectious diseases and responding to public health emergencies.

China Launches National Nanopore Sequencing Project for Pathogen Infections

A national major science and technology project has been launched to accelerate the application of nanopore sequencing in the field of pathogen infection. This initiative aims to leverage advanced sequencing technology for improved diagnostics and research in infectious diseases, contributing to public health preparedness and response capabilities.

China Launches National R&D Program for Nanopore Sequencing in Pathogen Detection

A national key R&D program was launched on March 16, 2026, to accelerate the application of nanopore sequencing in the field of pathogen infection detection. This initiative aims to enhance the speed and accuracy of identifying infectious agents, which is crucial for public health response and disease control. The program will foster innovation and collaboration in genomic sequencing technologies for medical diagnostics.

BGI Genomics Reveals cfDNA Genetic Code for Liquid Biopsy

BGI Genomics, in collaboration with Wuhan Children's Hospital and others, has revealed the 'genetic code' of cfDNA's intrinsic characteristics. This breakthrough opens new avenues for the precision of liquid biopsies, particularly in cancer early screening and non-invasive prenatal testing (NIPT). The findings shed light on the 'fragmentomics' of cfDNA.